Last reviewed · How we verify
Low-dose OKN-007, BID
At a glance
| Generic name | Low-dose OKN-007, BID |
|---|---|
| Sponsor | Oblato, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |